GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
TUESDAY, Sept. 23, 2025 -- In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes, according to a study published online Sept. 15 in JAMA Pediatrics.
Pareeta Kotecha, Pharm.D., from the University of Florida in Gainesville, and colleagues examined the efficacy and safety of GLP-1 RAs in children and adolescents with obesity, prediabetes, or T2D in a systematic review. Data were included from 18 randomized controlled trials, with 1,402 participants (838 GLP-1 RA users and 564 receiving placebo).
The researchers found significant reductions in hemoglobin A1c (−0.44 percent), fasting glucose (−9.92 mg/dL), body weight (−3.02 kg), body mass index (BMI; 1.45 kg/m2), BMI standard deviation score (−0.20), BMI percentile (−7.24 percent), and systolic blood pressure (−2.73 mm Hg) in association with GLP-1 RAs and an increase in gastrointestinal adverse effects (log rate ratio, 0.75). No significant differences were seen in other adverse events, including suicidal ideation or behaviors.
"This systematic review and meta-analysis provides a comprehensive evaluation of the benefits and risks associated with GLP-1 RAs in the pediatric population, enabling patients, caregivers, and clinicians to make more informed treatment decisions," the authors write.
One author disclosed ties to the biopharmaceutical industry; a second author is proprietor of Wisdom of Meraki.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Hormone Replacement Therapy Patches Safer Than Oral Delivery for Women With Diabetes
FRIDAY, Sept. 19, 2025 -- Hormone replacement therapy (HRT) patches carry lower cardiovascular risk than oral HRT among women with type 2 diabetes, according to a study presented...
Cannabis Use Increases Diabetes Risk Nearly Fourfold
FRIDAY, Sept. 19, 2025 -- Cannabis use is associated with a nearly quadrupled risk for developing type 2 diabetes, according to a study presented at the annual meeting of the...
Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
THURSDAY, Sept. 18, 2025 -- In adults with obesity and those with type 2 diabetes and obesity, once-weekly semaglutide 7.2 mg is superior to placebo for body weight reduction...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.